Found: 10
Select item for more details and to access through your institution.
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
- Published in:
- Cancer Reports, 2022, v. 5, n. 11, p. 1, doi. 10.1002/cnr2.1603
- By:
- Publication type:
- Article
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 3, p. 430, doi. 10.1111/bjh.14870
- By:
- Publication type:
- Article
Clinical applications of palifermin: amelioration of oral mucositis and other potential indications.
- Published in:
- Journal of Cellular & Molecular Medicine, 2013, v. 17, n. 11, p. 1371, doi. 10.1111/jcmm.12169
- By:
- Publication type:
- Article
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 7, p. 1117, doi. 10.1002/psp4.13144
- By:
- Publication type:
- Article
Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 4, p. 1044, doi. 10.1002/art.38293
- By:
- Publication type:
- Article
First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 3, p. 429, doi. 10.1111/cts.13467
- By:
- Publication type:
- Article
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 5, p. 667, doi. 10.1007/s11523-023-00989-z
- By:
- Publication type:
- Article
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 4, p. 433, doi. 10.1007/s11523-022-00893-y
- By:
- Publication type:
- Article